BioCentury
ARTICLE | Financial News

Saladax raises $22.4 million in series D

March 6, 2013 2:28 AM UTC

Saladax Biomedical Inc. (Bethlehem, Pa.) raised $22.4 million in a series D round from Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196). Saladax granted a division of Shanghai Fosun exclusive commercialization rights in China to Saladax's portfolio of MyCare oncology dose management assays. The portfolio includes the My5-FU diagnostic test, a nanoparticle-based immunoassay that measures 5-fluorouracil (5-FU) blood plasma levels. UBS advised Saladax. ...